Key result
Selective serotonin reuptake inhibitor use was not associated with reduced risk of incident cardiovascular disease compared with non-SSRI antidepressants (e.g., HR for MI 0.91; 95% CI 0.64-1.29).
Why the study?
The association of antidepressant medication type with the risk of cardiovascular disease is unclear.
Does SSRI use reduce the incidence of cardiovascular disease compared to non-SSRI antidepressants in patients treated with antidepressants?
Cohort (n=2,027)
Yes
Does SSRI use reduce the incidence of cardiovascular disease compared to non-SSRI antidepressants in patients treated with antidepressants?
Effect estimate: HR 1.10 (AF), HR 0.98 (HF), HR 0.91 (MI), HR 1.07 (stroke) (95% CI 0.86-1.41 (AF), 0.77-1.25 (HF), 0.64-1.29 (MI), 0.70-1.63 (stroke))
SSRI use is not associated with a reduced risk of incident cardiovascular disease compared with non-SSRI antidepressants.
No takes yet. Share an insight, caveat, or question.
No support for preferring SSRIs to lower CVD risk among antidepressant users; observational data leave open a possible benefit for randomized confirmation.
Almuwaqqat et al. (2019) conducted a cohort in Antidepressant users (n=2,027). Selective serotonin reuptake inhibitors (SSRIs) vs. Tricyclics and other non-SSRI antidepressants was evaluated on Cardiovascular disease events (atrial fibrillation, heart failure, myocardial infarction, and ischemic stroke) (HR 1.10 (AF), HR 0.98 (HF), HR 0.91 (MI), HR 1.07 (stroke), 95% CI 0.86-1.41 (AF), 0.77-1.25 (HF), 0.64-1.29 (MI), 0.70-1.63 (stroke)). Selective serotonin reuptake inhibitor use was not associated with reduced risk of incident cardiovascular disease compared with non-SSRI antidepressants (e.g., HR for MI 0.91; 95% CI 0.64-1.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: